PH12021553151A1 - Salts of a compound, crystal forms of the salts and preparation method and use thereof - Google Patents

Salts of a compound, crystal forms of the salts and preparation method and use thereof

Info

Publication number
PH12021553151A1
PH12021553151A1 PH1/2021/553151A PH12021553151A PH12021553151A1 PH 12021553151 A1 PH12021553151 A1 PH 12021553151A1 PH 12021553151 A PH12021553151 A PH 12021553151A PH 12021553151 A1 PH12021553151 A1 PH 12021553151A1
Authority
PH
Philippines
Prior art keywords
salts
fluorine
acid salt
compound
preparation
Prior art date
Application number
PH1/2021/553151A
Other languages
English (en)
Inventor
Zhenglin Yao
Lei Yin
Original Assignee
Gan & Lee Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=74040655&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12021553151(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gan & Lee Pharmaceuticals Co Ltd filed Critical Gan & Lee Pharmaceuticals Co Ltd
Publication of PH12021553151A1 publication Critical patent/PH12021553151A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH1/2021/553151A 2019-06-21 2020-06-22 Salts of a compound, crystal forms of the salts and preparation method and use thereof PH12021553151A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910542355 2019-06-21
PCT/CN2020/097482 WO2020253875A1 (zh) 2019-06-21 2020-06-22 一种化合物的盐、其晶型以及制备方法与应用

Publications (1)

Publication Number Publication Date
PH12021553151A1 true PH12021553151A1 (en) 2022-07-25

Family

ID=74040655

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2021/553151A PH12021553151A1 (en) 2019-06-21 2020-06-22 Salts of a compound, crystal forms of the salts and preparation method and use thereof

Country Status (16)

Country Link
US (1) US20220168302A1 (enExample)
EP (1) EP3988546A4 (enExample)
JP (1) JP2022538076A (enExample)
KR (1) KR20220041090A (enExample)
CN (1) CN115708409A (enExample)
AR (1) AR119184A1 (enExample)
AU (1) AU2020296048A1 (enExample)
BR (1) BR112021025944A2 (enExample)
CA (1) CA3144546A1 (enExample)
CL (1) CL2021003438A1 (enExample)
CO (1) CO2022000502A2 (enExample)
IL (1) IL289231A (enExample)
MX (1) MX2022000051A (enExample)
PH (1) PH12021553151A1 (enExample)
WO (1) WO2020253875A1 (enExample)
ZA (1) ZA202200964B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022042738A1 (zh) * 2020-08-31 2022-03-03 甘李药业股份有限公司 一种含cdk4/6抑制剂的药物组合物
US20250332167A1 (en) * 2021-05-17 2025-10-30 Gan & Lee Pharmaceuticals Co., Ltd. Pharmaceutical use of cdk 4/6 inhibitor
EP4696689A1 (en) * 2023-04-04 2026-02-18 Suzhou Kintor Pharmaceuticals, Inc. Salt form and crystal form of chiral heterocyclic compound having hedgehog pathway antagonist activity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK9742002A3 (en) * 2000-01-07 2003-02-04 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
CN106810536A (zh) * 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途

Also Published As

Publication number Publication date
CA3144546A1 (en) 2020-12-24
EP3988546A4 (en) 2023-05-17
EP3988546A1 (en) 2022-04-27
AR119184A1 (es) 2021-12-01
KR20220041090A (ko) 2022-03-31
MX2022000051A (es) 2022-05-24
CO2022000502A2 (es) 2022-01-28
US20220168302A1 (en) 2022-06-02
AU2020296048A1 (en) 2022-02-10
BR112021025944A2 (pt) 2022-02-08
CN115708409A (zh) 2023-02-21
WO2020253875A1 (zh) 2020-12-24
CL2021003438A1 (es) 2022-09-30
JP2022538076A (ja) 2022-08-31
IL289231A (en) 2022-02-01
ZA202200964B (en) 2022-08-31

Similar Documents

Publication Publication Date Title
MX2019011785A (es) Proceso para preparar compuestos de 2,3-dihidrotiazolo[3,2-a]pirim idin-4-io quirales.
MX2022000051A (es) Sales de un compuesto, formas cristalinas de las sales y metodo de preparacion y uso de las mismas.
MX2020011294A (es) Derivados de 2-amino-piridina o 2-amino-pirimidina como inhibidores de cinasa dependientes de ciclina.
WO2017075257A3 (en) High intensity sweeteners
CA3010509A1 (en) Substituted thiohydantoin derivatives as androgen receptor antagonists
MY186830A (en) A novel carystalline from of a benzimidazole derivative and a preparation method thereof
EA201991055A1 (ru) СПОСОБ ПОЛУЧЕНИЯ ПИРАЗОЛ[1,5-a]ПИРИМИДИНОВ И ИХ СОЛЕЙ
EA201001813A1 (ru) Замещенные 1-(диазинил)пиразол-4-ил-уксусные кислоты, способ их получения и их применение в качестве гербицидов и регуляторов роста растений
WO2020083733A8 (en) Pesticidal compounds
ZA202201503B (en) Urea compound for antagonizing lpa1 receptor
EA201792433A1 (ru) Производные 2-(фенилокси- или фенилтио)пиримидина в качестве гербицидов
WO2020141419A3 (en) Novel salts and polymorphic form of bempedoic acid
WO2017177004A8 (en) Tertiary amides and method of use
WO2018102315A8 (en) Polymorphs of sepiapterin and salts thereof
MX2019007120A (es) Compuestos plaguicidas.
EA202091906A1 (ru) Предотвращение или уменьшение роста растений путем биоцементации
MX2020013899A (es) Derivados de pirazol como inhibidores de malt1.
MY195159A (en) High Density Aqueous Well Fluids
PH12018502201B1 (en) Herbicidal pyridazinone compounds
ZA201805185B (en) Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms
MX2020009337A (es) Compuestos herbicidas.
WO2016071361A3 (en) Herbicidal compounds
ZA202004342B (en) Pesticidal compounds
MX2016000669A (es) Compuestos plaguicidas.
MY202702A (en) Herbicidal compounds